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Acute liver failure (ALF) is a rare condition character-
ized by new and rapidly evolving hepatic dysfunction
associated with neurological dysfunction and coagul-
opathy. It is more frequent in young individuals, and its
causes vary geographically, with impact on both clini-
cal course and outcomes. Throughout the last few dec-
ades, ALF outcomes have been improving in the
context of the optimized overall management. Howev-
er, its present morbidity and mortality are still of
concern.
DEFINITION AND EPIDEMIOLOGY
ALF definition has evolved and currently includes the
following features: international normalized ratio (INR) 
1.5, neurological dysfunction with any degree of hepat-
ic encephalopathy (HE), no preexisting cirrhosis, and dis-
ease course 26 weeks. ALF causes are summarized in
Table 1 and corresponding investigations in Table 2.
ALF outcomes have been improving in recent decades.
In a multicenter registry from the United States in 1998
to 2010, ALF 2-year survival rate has been reported as
92% for liver transplant (LT) recipients, 90% for acet-
aminophen overdose spontaneous survivors, and 76%
for nonacetaminophen spontaneous survivors.1 This
positive trend in ALF survival has been associated with
the earlier recognition of this condition, improvement of
the intensive care unit management, and developments
in emergent LT.
Abbreviations: ALFSG, Acute Liver Failure Study Group; ALT, alanine aminotransferase; AKI, acute kidney injury; ALF, acute liver
failure; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CMV, cytomegalovirus; EBV, Epstein-Barr
virus; HAV, hepatitis A virus; HBc, hepatitis B virus core antibody; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus;
HE, hepatic encephalopathy; HELLP, hemolysis, elevated liver enzymes, and low platelets; HEV, hepatitis E virus; HIV, human immu-
nodeficiency virus; HSV, herpes simplex virus; HVP, high-volume plasmapheresis; Ig, immunoglobulin; INR, international normalized
ratio; LDH, lactate dehydrogenase; LT, liver transplant; MARS, molecular adsorbent recirculating system; MDMA, 3,4-methylene-
dioxy-N-methylamphetamine; SIRS, systemic inflammatory response syndrome; VZV, varicella zoster virus.
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MANAGEMENT OF THE PATIENT WITH ACUTE
LIVER FAILURE
A summary of organ failure complications of ALF is
provided in Table 3.
Coagulopathy
In ALF, overall hemostasis as measured by thromboe-
lastography has been shown to be normal by several
compensatory mechanisms, even in patients with mark-
edly elevated INR.2 In the absence of active bleeding or
invasive procedure, it is not advisable to correct the INR
with fresh frozen plasma, because clinically significant
blood loss is rare and correction obscures trends in the
INR, an important marker of prognosis. A platelet count
greater than 503109/L and fibrinogen greater than 1.5
g/L have been demonstrated to correlate with normal
thrombin generation and, indirectly, bleeding.3
Infection
ALF risk for immunoparesis increases susceptibility to
infection, which may preclude emergent LT. Therefore,
surveillance for infection (including chest radiography and
periodic cultures of sputum, urine, and blood) should be
undertaken, while maintaining a low threshold for starting
antimicrobial therapy. Prophylactic antimicrobials have not
been proven to improve 21-day survival in ALF.4
Hemodynamics
Patients with ALF typically present a hyperdynamic cir-
culation characterized by high cardiac output and low
peripheral vascular resistance, a pattern resembling that
of sepsis. For patients who continue to have hypotension
despite volume repletion, noradrenaline is the preferred
vasopressor, with or without adjunctive use of vasopres-
sin or its analogues.5 Echocardiography or invasive hemo-
dynamic monitoring (e.g., PiCCO, Swan-Ganz catheter)
should be used to assess cardiac function and help titrate
decisions on the doses of fluids and/or vasopressors. Rel-
ative adrenal insufficiency may be present, and the use
of steroids has been associated with a decrease in nor-
adrenaline dose and overall mortality.
TABLE 1. ACUTE LIVER FAILURE CAUSATIVE FACTORS
Viruses
Hepatitis A, B, D, or E viruses
Cytomegalovirus
Epstein-Barr virus
Herpes simplex virus
Varicella zoster virus
Parvovirus
Drug-induced liver injury
Acetaminophen
Nonacetaminophen (e.g., isoniazid, phenytoin, valproate, propylthiouracil,
nitrofurantoin)
Recreational drugs (e.g., cocaine, MDMA)
Autoimmune hepatitis
Ischemic/congestive hepatitis
Budd-Chiari syndrome
Wilson’s disease
Amanita phalloides
Pregnancy (e.g., acute fatty liver of pregnancy, HELLP syndrome)
Heat stroke
Malignant infiltration
Seronegative (indeterminate)
Abbreviations: HELLP, hemolysis, elevated liver enzymes, and low
platelets; MDMA, 3,4-methylenedioxy-N-methylamphetamine.
TABLE 2. INITIAL LABORATORY TESVTS FOR ACUTE
LIVER INJURY OR ACUTE LIVER FAILURE
Assessment Test
Severity (serum) Arterial blood gas
Arterial lactate
Arterial ammonia
Hemoglobin, leucocytes, platelets
INR, aPTT, fibrinogen, factor V
AST, ALT, bilirubin, albumin, alkaline
phosphatase, LDH, amylase
Creatinine, urea, sodium, chloride, potassium,
calcium, magnesium, phosphorus, creatine kinase
Etiology (serum
or urine)
HAV IgM, HBsAg, HBc IgM, anti-HCV, anti-HEV,
CMV IgM, EBV IgM, HSV IgM, VZV IgM, anti-HIV
Ceruloplasmin, copper
Anti-nuclear antibody, anti-smooth muscle
antibody, Igs
Paracetamol, toxicology screen
Blood type
Pregnancy test (females)
Abbreviations: ALT, alanine aminotransferase; aPTT, activated par-
tial thromboplastin time; AST, aspartate aminotransferase; CMV, cyto-
megalovirus; EBV, Epstein-Barr virus; HAV, hepatitis A virus; HBc,
hepatitis B virus core antibody; HBsAg, hepatitis B virus surface antigen;
HCV, hepatitis C virus; HEV, hepatitis E virus; HIV, human immunodefi-
ciency virus; HSV, herpes simplex virus; Ig, immunoglobulin; LDH, lac-
tate dehydrogenase; VZV, varicella zoster virus.
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Acute Kidney Injury
Acute kidney injury (AKI) may develop in up to 70% of
patients with ALF and has been associated with worse
overall survival.6 Classic indications for renal replacement
therapy initiation also apply, including severe acidosis,
hyperkalemia, anuria, and/or fluid overload. Further indi-
cations may include removal of toxic substances (e.g.,
ammonia), difficult-to-treat hyponatremia, or difficult-to-
treat hyperthermia. Continuous renal replacement thera-
py has been proposed to safer for patients with ALF
given the risk for aggravating hypotension and cerebral
edema.7
Cerebral Edema and Intracranial Hypertension
In ALF, astrocyte swelling may result in cytotoxic brain
edema, which may culminate in tonsillar herniation and
death. Frequent neurological examination (including
pupils) and the use of transcranial Doppler are simple
strategies to monitor for signs of cerebral edema and
intracranial pressure. On the contrary, computed tomo-
graphic findings compatible with intracranial hyperten-
sion often present too late in the course of this
condition. Invasive monitoring of intracranial pressure
has not been shown to improve these patients’ hospital
survival.8 Nevertheless, it is still not clear whether
patients with the highest risk for cerebral edema and
intracranial hypertension (e.g., ammonia level > 150
mmol/L, vasopressors requirement, or renal replacement
therapy requirement) may benefit from such monitoring
capacity.9 Interventions aimed at prevention of intracrani-
al hypertension include: (1) place head of the bed higher
than 30 degrees; (2) use propofol sedation if requiring
mechanical ventilation; (3) treat fever (prophylactic hypo-
thermia has not been demonstrated to mitigate intracra-
nial hypertension)10; (4) aim for a mean arterial pressure
75 mm Hg and a cerebral perfusion pressure greater
than 50 mm Hg (if using invasive intracranial pressure
monitoring); (5) consider using renal replacement thera-
py; and (6) aim for a serum sodium concentration of 145
to 155 mmol/L with hypertonic saline (3%-30% infusion)
for prophylaxis in patients with grade III-IV HE.
Extracorporeal Liver Support Systems
Two extracorporeal liver support systems have been
studied in ALF with randomized controlled trials: molecu-
lar adsorbent recirculating system (MARS) and high-
volume plasmapheresis (HVP). MARS, where blood is dia-
lyzed against a dialysate with albumin, has not been
proven to improve 6-month survival in ALF.11 HVP has
been shown to significantly improve hospital survival,
especially for patients with contraindications for LT.12
LIVER TRANSPLANTATION AND
PROGNOSTICATION
LT is the only definitive treatment for patients with
ALF. Overall survival after LT has been reported to be
lower for patients with ALF in comparison with patients
with cirrhosis until 1 year after transplant, but it tends to
be similar beyond this period. Cadaveric donor LT has
been the norm in ALF, but living-donor transplant has
been performed in some large-volume centers with
acceptable outcomes. Auxiliary transplantation (partial
graft as temporary support for native liver regeneration)
has shown reasonable outcomes. Stratifying patients
based on their risk for death without LT is crucial to pri-
oritize them for transplantation. King’s College criteria
have been used worldwide for this purpose (Table 4). A
recent meta-analysis has revealed its prognostic ability in
comparison with the Model for End-Stage Liver Disease
TABLE 3. ORGAN COMPLICATIONS OF ACUTE
LIVER FAILURE
Organ Failure Pathophysiology
Liver Hyperlactatemia: decreased lactate clearance
Hyperammonemia: decreased ammonia clearance
Coagulopathy: decreased synthesis of
procoagulant and anticoagulant factors
Hypoglycemia: decreased gluconeogenesis
Portal hypertension: may develop especially
in subacute disease
Brain HE: circulating inflammatory mediators and
hyperammonemia
Cerebral edema: inflammatory mediators from
microglial cells and glutamine accumulation
in astrocytes
Cardiovascular Hypotension or shock, especially if sepsis
superimposes
Lungs Acute lung injury or acute respiratory distress
syndrome: SIRS, sepsis, and/or fluid overload
Kidneys AKI: SIRS, sepsis, and/or hypovolemia
Pancreas Acute pancreatitis: SIRS and/or drug toxicity
(e.g., paracetamol)
Abbreviation: SIRS, systemic inflammatory response syndrome.
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score: for paracetamol-related ALF, sensitivities were 58%
and 80%, respectively, and specificities were 89% and
53%, respectively; for nonparacetamol causes, sensitivities
were 58% and 76%, respectively, and specificities were
74% and 73%, respectively. Therefore, King’s College cri-
teria remain highly specific for paracetamol-related ALF,
but less accurate for nonparacetamol causative factors.
More recently, the US Acute Liver Failure Study Group
(ALFSG) prognostic index showed good performance char-
acteristics (C-statistic 0.84, specificity 95%) in 1974
patients in the ALFSG registry.13 This is demonstrated in
Table 4 and is a commercially available app.
CONCLUSIONS
ALF diagnostic and therapeutic strategies have evolved
and are now associated with improved outcomes. New
advances in basic and clinical research may potentiate
even more such outcomes. Despite this, early patient
referral to an LT center, timely intensive care unit thera-
py, and a comprehensive multidisciplinary strategy in risk
stratification and selection for LT will continue to be fun-
damental steps for a successful approach.
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